Study of the Immunohistochemical Expression of p63 in Benign Lesions and Carcinoma of the Breast at a Tertiary Hospital in South India

Shreya Dinesh Prabhu; Hassan Sona Rai; Rakshatha Nayak; Ramadas Naik; Shikha Jayasheelan

doi:10.7759/cureus.48557

Study of the Immunohistochemical Expression of p63 in Benign Lesions and Carcinoma of the Breast at a Tertiary Hospital in South India

Cureus. 2023 Nov 9;15(11):e48557. doi: 10.7759/cureus.48557. eCollection 2023 Nov.

Authors

Shreya Dinesh Prabhu¹, Hassan Sona Rai², Rakshatha Nayak³, Ramadas Naik⁴, Shikha Jayasheelan³

Affiliations

¹ Pathology, Rajarajeswari Medical College and Hospital, Bengaluru, IND.
² Pathology, BGS Global Institute of Medical Sciences, Bengaluru, IND.
³ Pathology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, IND.
⁴ Pathology, Yenepoya Medical College, Mangalore, IND.

Abstract

Background: Invasive breast carcinoma is among the most common female cancers worldwide, causing high morbidity and mortality. Considerable disagreement in the interpretation of diagnostically challenging breast lesions based on histology alone has been documented. One of the essential histopathological findings that help distinguish benign from malignant lesions is the presence of the myoepithelial cell layer. Myoepithelial markers such as tumor protein 63 (p63) help distinguish invasive carcinoma from benign proliferations. p63 antibody is superior to other myoepithelial markers as it selectively stains the nuclei and is negative in stromal cells.

Objective: To study the expression of p63 in various histological subtypes and grades of breast carcinomas.

Methods: After routine hematoxylin and eosin stain, 65 cases of breast lesions were subjected to immunohistochemistry for p63 antigen using Novacastra ready-to-use monoclonal antibody p6. All cases were analyzed for p63 expression, and its staining arrangement was interpreted.

Results: In all benign lesions, immunoreactivity was noted in the myoepithelial cells, forming a continuous layer surrounding the luminal epithelial cells. The benign papillary lesions showed p63 staining in the fibrovascular core of the papillary fronds and at the periphery. A few single myoepithelial cells stained by p63 were also seen scattered discontinuously in ductal carcinoma in situ (DCIS). All invasive carcinomas and encapsulated papillary carcinomas were completely devoid of peripheral p63 staining of myoepithelial cells.

Conclusion: p63 is a specific nuclear marker of myoepithelial cells in the breast and can, therefore, aid in distinguishing invasive ductal carcinoma from DCIS or rare questionable hyperplastic lesions. They also play a significant role in distinguishing various papillary lesions of the breast and, hence, can be incorporated into routine reporting for definitive diagnosis and accurate treatment.

Keywords: ductal carcinoma in situ; immunohistochemistry; invasive breast carcinoma; myoepithelial cells; p63.